The drug, imlunestrant, improved progression-free survival in patients whose breast cancer was driven by the female hormone estrogen. The drug was particularly effective in breast cancers with a ...

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive ...

The drug, imlunestrant, was especially effective when combined with a second drug, abemaciclib (Verzenio ®). The combination reduced the risk of cancer progression or death by more than 40%, compared ...

Among 426 patients in the comparison of imlunestrant–abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI ...

Healthcare giant Eli Lilly’s Phase III EMBER-3 study in patients with advanced breast cancer showed imlunestrant, cut the ...

T HURSDAY, Dec. 12, 2024 (HealthDay News) -- For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, imlunestrant leads ...

Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive ...

When combined with Lilly’s approved medicine Verezenio, the experimental drug, called imlunestrant, also helped women stay ...

SAN ANTONIO — Second-line treatment with imlunestrant improved progression-free survival compared with standard endocrine monotherapy in patients with advanced estrogen receptor (ER)–positive ...

Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, or SERD, in patients with estrogen receptor ...